NYSE:MD - MEDNAX Stock Price, Forecast & News

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

MEDNAX Inc (NYSE:MD) posted its quarterly earnings data on Thursday, February, 20th. The company reported $0.91 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.83 by $0.08. The firm earned $905.38 million during the quarter, compared to analysts' expectations of $900.85 million. MEDNAX had a negative net margin of 42.63% and a positive return on equity of 12.22%. The firm's quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the company posted $0.92 EPS. View MEDNAX's Earnings History.

MEDNAX is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for MEDNAX.

MEDNAX updated its first quarter earnings guidance on Thursday, February, 20th. The company provided EPS guidance of $0.55 to $0.63 for the period, compared to the Thomson Reuters consensus estimate of $0.63.

11 equities research analysts have issued 1 year target prices for MEDNAX's stock. Their forecasts range from $18.00 to $34.00. On average, they anticipate MEDNAX's share price to reach $25.82 in the next twelve months. This suggests a possible upside of 51.1% from the stock's current price. View Analyst Price Targets for MEDNAX.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MEDNAX.

Press coverage about MD stock has trended extremely negative this week, InfoTrie reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. MEDNAX earned a news sentiment score of -4.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for MEDNAX.

MEDNAX saw a decline in short interest in the month of February. As of February 14th, there was short interest totalling 5,400,000 shares, a decline of 11.2% from the January 30th total of 6,080,000 shares. Based on an average trading volume of 1,030,000 shares, the short-interest ratio is presently 5.2 days. Currently, 6.7% of the company's shares are short sold. View MEDNAX's Current Options Chain.

Some companies that are related to MEDNAX include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), BioScrip (BIOS), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include Gilead Sciences (GILD), AbbVie (ABBV), Dominion Energy (D), Pfizer (PFE), Exxon Mobil (XOM), CVS Health (CVS), Chevron (CVX), Walt Disney (DIS), General Electric (GE) and AT&T (T).

MEDNAX's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (6.35%), P2 Capital Partners LLC (4.63%), State Street Corp (2.59%), FMR LLC (2.02%), LSV Asset Management (1.54%) and Prudential Financial Inc. (1.52%). Company insiders that own MEDNAX stock include David A Clark, Dominic J Andreano, John C Pepia, Joseph M Calabro, Md Pascal J Goldschmidt, Michael Fernandez and Vivian Lopez-Blanco. View Institutional Ownership Trends for MEDNAX.

MD stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, FMR LLC, Panagora Asset Management Inc., State Street Corp, Goldman Sachs Group Inc., Man Group plc, AlphaCrest Capital Management LLC and Stone Ridge Asset Management LLC. Company insiders that have sold MEDNAX company stock in the last year include David A Clark, Dominic J Andreano, Joseph M Calabro and Md Pascal J Goldschmidt. View Insider Buying and Selling for MEDNAX.

MD stock was acquired by a variety of institutional investors in the last quarter, including P2 Capital Partners LLC, Great Lakes Advisors LLC, LSV Asset Management, Renaissance Technologies LLC, Bank of New York Mellon Corp, William Blair Investment Management LLC, Schroder Investment Management Group and Mackay Shields LLC. View Insider Buying and Selling for MEDNAX.

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MD stock can currently be purchased for approximately $17.09.

MEDNAX has a market capitalization of $1.44 billion and generates $3.51 billion in revenue each year. The company earns $-1,497,700,000.00 in net income (profit) each year or $3.14 on an earnings per share basis. MEDNAX employs 7,625 workers across the globe.View Additional Information About MEDNAX.

The official website for MEDNAX is http://www.mednax.com/.

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at 954-384-0175 or via email at [email protected]